BI 894999 First in Human Dose Finding Study in Advanced Malignancies

  • STATUS
    Recruiting
  • End date
    Dec 1, 2021
  • participants needed
    204
  • sponsor
    Boehringer Ingelheim
Updated on 1 August 2021
tyrosine
lymphoma
measurable disease
carcinoma
growth factor
endocrine therapy
lung cancer
treatment regimen
bilateral oophorectomy
anthracyclines
metastasis
hormone therapy
fluoropyrimidine
EGFR
bevacizumab
docetaxel
advanced cancer
primary cancer
neuropathy
adenocarcinoma
solid tumour
alopecia
solid neoplasm
sarcoma
taxane
pet/ct scan
malignant solid neoplasm

Summary

This study is open to adults with different types of advanced cancer (solid tumours). The study is also open to patients with diffuse large B-cell lymphoma in whom previous treatment was not successful. In some countries, adolescents who are at least 15 years old and who are diagnosed with NUT carcinoma can also participate. No standard treatment exists for this rare and aggressive form of cancer.

The purpose of this study is to find out the highest dose of BI 894999 that people can tolerate.

BI 894999 is tested for the first time in humans. Participants take tablets once daily. The study also tests whether participants can tolerate BI 894999 better when taken continuously or with breaks in between.

Participants can stay in the study as long as they benefit from the treatment and can tolerate it.

The doctors also regularly check the general health of the participants.

Details
Condition Cancer, Cancer/Tumors, Ewing's Family Tumors, Cancer (Pediatric), Neoplasms, NUT Carcinoma
Treatment BI 894999
Clinical Study IdentifierNCT02516553
SponsorBoehringer Ingelheim
Last Modified on1 August 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note